Hannah A Blair
Hannah A Blair
Fremanezumab (fremanezumab-vfrm; AJOVY®) is a humanized monoclonal antibody developed by Teva Pharmaceuticals to selectively target calcitonin gene-related peptide (a vasodilatory neuropeptide involved in the pathophysiology of migraine). ...
Camila C Luz,Paulo F Collett-Solberg
Camila C Luz
Growth hormone (GH) has been used to treat severe GH deficiency for more than 60 years, with other indications dependent upon approval from national medical societies and governmental agencies. Many changes in GH preparations have been made...
Navigating the Biosimilars from Bench to Bedside in Juvenile Idiopathic Arthritis [0.03%]
从试验台到病床：幼年特发性关节炎生物类似药的开发与应用展望
Elaine M Yung,Amanda Fridley,Tracy Matheny et al.
Elaine M Yung et al.
Biosimilar use for pediatric rheumatologic conditions, such as juvenile idiopathic arthritis (JIA), is increasing owing to the development and release of multiple biosimilars into the US market. The US biosimilar development process of bio-...
Nicholas Ah Mew,Uta Lichter-Konecki
Nicholas Ah Mew
The urea cycle, a metabolic pathway comprising six enzymes and two transporters, is necessary for mammalian nitrogen detoxification. A deficiency of any of these components disrupts this process, leading to the accumulation of nitrogen in t...
Big Data in the Assessment of Medication Safety in Pregnancy: Opportunities and Challenges [0.03%]
大数据在评估孕期药物安全性方面的机遇与挑战
Per Damkier,Krista F Huybrechts,Hedvig Nordeng
Per Damkier
Editorial
Paediatric drugs. 2025 Sep 4. DOI:10.1007/s40272-025-00718-1 2025
Antipsychotic Medications for Delirium Treatment in the Pediatric Intensive Care Unit: A Systematic Review [0.03%]
儿童重症监护室抗精神病药物治疗谵妄的系统评价
Francesca Cavagnero,Annalisa Salerno,Chiara Marchegiani Rizzolli et al.
Francesca Cavagnero et al.
Background and objectives: Pediatric delirium (PD) is a common but underdiagnosed condition in pediatric intensive care units (PICUs), affecting 17-66% of patients. It is associated with prolonged ventilation and hospital...
Long-Term Efficacy and Safety of Secukinumab in Children and Adolescents with Moderate-to-Severe Chronic Plaque Psoriasis: Four-Year Results of a Randomized, Phase III, Open-Label Trial [0.03%]
Secukinumab治疗中至重度慢性斑块状银屑病儿童和青少年患者长期疗效及安全性的随机III期开放标签试验的四年结果
Kulli Kingo,Philemon Papanastasiou,Stefan Beissert et al.
Kulli Kingo et al.
Background: The efficacy and safety of secukinumab up to week 52 in children and adolescents with moderate-to-severe chronic plaque psoriasis have been demonstrated previously (NCT03668613). Herein, we report the long-ter...
Long-Term Safety of Anti-Interleukin-1 Medications in Children with Rheumatic Diseases: a Systematic Review [0.03%]
抗IL-1药物治疗风湿性疾病儿童的长期安全性系统评价研究
M Isa,G M Tiller,D F L Liew et al.
M Isa et al.
Background: Anti-interleukin-1 (IL-1) biologic disease-modifying anti-rheumatic drugs are the mainstay for several childhood rheumatic and autoinflammatory diseases. Long-term medication safety is a key consideration for ...
Comment on "Cardioprotective Effect of Nigella sativa in Pediatric Patients with Type 1 Diabetes Mellitus: A Randomized Controlled Study" [0.03%]
述评《肉桂籽对1型糖尿病患儿心血管保护作用的随机对照研究》
Syeda Samia Fatima
Syeda Samia Fatima
Authors' Reply to Fatima Comment on "Cardioprotective Effect of Nigella sativa in Pediatric Patients with Type 1 Diabetes Mellitus: A Randomized Controlled Study" [0.03%]
刺柏子对1型糖尿病患儿心脏保护作用的随机对照研究>Fatima述评的回答
Doaa El Amrousy,Dalia El-Afify
Doaa El Amrousy